Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license agreement (the "Agreement") with the MUSC Foundation for Research Development ("MUSC FRD"). Under the terms of...

Click to view original post